Allist(SH:688578) Xin Lang Cai Jing·2025-09-09 02:16Core Viewpoint - The stock of Ailis has shown significant growth in 2023, with a year-to-date increase of 97.82%, indicating strong market performance and investor interest [1][2]. Company Overview - Ailis Pharmaceutical Technology Co., Ltd. was established on March 22, 2004, and went public on December 2, 2020. The company is primarily engaged in the research, production, and sales of innovative drugs [1]. - The main revenue source for Ailis is drug sales, accounting for 99.93% of total revenue, with promotional services contributing 0.06% [1]. Financial Performance - For the first half of 2025, Ailis reported a revenue of 2.374 billion yuan, representing a year-on-year growth of 50.57%. The net profit attributable to shareholders was 1.051 billion yuan, reflecting a 60.22% increase compared to the previous year [2]. - Since its A-share listing, Ailis has distributed a total of 653 million yuan in dividends [3]. Shareholder Structure - As of June 30, 2025, Ailis had 13,000 shareholders, an increase of 3.61% from the previous period. The average number of circulating shares per shareholder was 34,578, down by 3.48% [2]. - Notable institutional shareholders include the Huaxia SSE STAR 50 ETF, which holds 12.42 million shares, and the Hong Kong Central Clearing Limited, which holds 10.38 million shares [3].